Genetic Diseases
1
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
EP
GenomicsUK - Oxford
3 programsGenomic sequencing and molecular diagnostic results, if anyN/A1 trial
Genomic sequencing and molecular diagnostic results, if anyN/A1 trial
Genomic sequencing and molecular diagnostic results, if any.N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eloxx PharmaceuticalsELX-02
GenomicsGenomic sequencing and molecular diagnostic results, if any
GenomicsGenomic sequencing and molecular diagnostic results, if any.
GenomicsGenomic sequencing and molecular diagnostic results, if any
Clinical Trials (4)
Total enrollment: 202,213 patients across 4 trials
Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Start: Jul 2016Est. completion: May 2017
Phase 1Terminated
Rapid Whole Genome Sequencing Study
Start: Aug 2017Est. completion: Dec 2050100,000 patients
N/AEnrolling By Invitation
Perinatal Precision Medicine
Start: Jun 2017Est. completion: Jul 2024213 patients
N/AUnknown
Rady Children's Institute Genomic Biorepository
Start: Jul 2016Est. completion: Dec 2050102,000 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 202,213 patients
2 companies competing in this space